Overview: Histone TestIntroduction: The Histone Test tests for anti-histone antibodies to diagnose drug-induced lupus or systemic lupus erythematosus, causing joint pain or rashes, aiding in diagnosis. Affecting 1 in 10,000 people with lupus, these conditions pose diagnostic challenges due to drug triggers. Following 2023 American College of Rheumatology (ACR) guidelines, it uses ELISA for high sensitivity, supporting immunology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in rheumatology.
Other Names: Anti-Histone Antibody Test, Lupus Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Autoantibody testing began in the 1970s with research by Tan, who identified anti-histone antibodies. ELISA advancements in the 1990s by Thermo Fisher improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects anti-histone antibodies to diagnose lupus, guides immunosuppressive therapy, and evaluates patients with joint pain, aiming to manage symptoms.
Test Parameters: Anti-histone antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of lupus or drug use.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document joint pain, rashes, or lupus history. Include current medications or drug exposure.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., kidney damage), and sample collection risks.
Procedural Considerations: Uses ELISA to measure antibodies, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive antibodies confirm lupus, guiding therapy. Early treatment might prevent complications, while untreated cases lead to worsening. Normal levels may require other autoantibody tests.
Specialist Consultation: Consult a rheumatologist for interpretation.
Additional Supporting Tests: ANA test, anti-dsDNA, or biopsy to confirm diagnosis.
Test Limitations: Specific to histone antibodies; correlation with symptoms needed. False positives possible with other autoimmune diseases.
References: ACR Guidelines, 2023; Arthritis & Rheumatology, Tan EM, 2022.
